In contrast, low immune infiltration of luminal BC and low expression of TILs and PD-L1 (99) lead to patients being insensitive to immunotherapy, but the therapeutic effect can be enhanced by adjusting the microenvironment by increasing antigen presentation (100) and reversing immunosuppression (101). Here, CD274 is linked to breast cancer.